HRP20000256A2 - Use of thiazolidinediones for the treatment of hyperglycaemia - Google Patents
Use of thiazolidinediones for the treatment of hyperglycaemia Download PDFInfo
- Publication number
- HRP20000256A2 HRP20000256A2 HR20000256A HRP20000256A HRP20000256A2 HR P20000256 A2 HRP20000256 A2 HR P20000256A2 HR 20000256 A HR20000256 A HR 20000256A HR P20000256 A HRP20000256 A HR P20000256A HR P20000256 A2 HRP20000256 A2 HR P20000256A2
- Authority
- HR
- Croatia
- Prior art keywords
- hyperglycemia
- glucose level
- compound
- plasma glucose
- insulin sensitiser
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9721692.3A GB9721692D0 (en) | 1997-10-13 | 1997-10-13 | Novel treatment |
| PCT/GB1998/003067 WO1999018944A1 (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20000256A2 true HRP20000256A2 (en) | 2000-12-31 |
Family
ID=10820481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20000256A HRP20000256A2 (en) | 1997-10-13 | 1998-10-12 | Use of thiazolidinediones for the treatment of hyperglycaemia |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1023057A1 (pt) |
| JP (1) | JP2001519383A (pt) |
| KR (1) | KR20010024482A (pt) |
| CN (1) | CN1281358A (pt) |
| AP (1) | AP1223A (pt) |
| AU (1) | AU9547198A (pt) |
| BG (1) | BG104405A (pt) |
| BR (1) | BR9815220A (pt) |
| CA (1) | CA2305289A1 (pt) |
| CZ (1) | CZ20001298A3 (pt) |
| EA (1) | EA200000418A1 (pt) |
| GB (1) | GB9721692D0 (pt) |
| HR (1) | HRP20000256A2 (pt) |
| HU (1) | HUP0003673A3 (pt) |
| ID (1) | ID24439A (pt) |
| IL (1) | IL135515A0 (pt) |
| NO (1) | NO20001897L (pt) |
| OA (1) | OA11519A (pt) |
| PL (1) | PL339804A1 (pt) |
| SK (1) | SK5322000A3 (pt) |
| TR (1) | TR200000957T2 (pt) |
| UA (1) | UA66809C2 (pt) |
| WO (1) | WO1999018944A1 (pt) |
| YU (1) | YU28700A (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| AP2001002036A0 (en) * | 1998-07-21 | 2001-03-31 | Smithkline Beecham Plc | Use of glucose uptake enhancer for reducing apoptosis. |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0306228B1 (en) * | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| US5457109A (en) * | 1993-09-15 | 1995-10-10 | Warner-Lambert Company | Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
-
1997
- 1997-10-13 GB GBGB9721692.3A patent/GB9721692D0/en not_active Ceased
-
1998
- 1998-10-12 CA CA002305289A patent/CA2305289A1/en not_active Abandoned
- 1998-10-12 CZ CZ20001298A patent/CZ20001298A3/cs unknown
- 1998-10-12 PL PL98339804A patent/PL339804A1/xx unknown
- 1998-10-12 HR HR20000256A patent/HRP20000256A2/hr not_active Application Discontinuation
- 1998-10-12 BR BR9815220-3A patent/BR9815220A/pt not_active Application Discontinuation
- 1998-10-12 IL IL13551598A patent/IL135515A0/xx unknown
- 1998-10-12 EP EP98949088A patent/EP1023057A1/en not_active Withdrawn
- 1998-10-12 AP APAP/P/2000/001788A patent/AP1223A/en active
- 1998-10-12 KR KR1020007003935A patent/KR20010024482A/ko not_active Ceased
- 1998-10-12 JP JP2000515579A patent/JP2001519383A/ja active Pending
- 1998-10-12 SK SK532-2000A patent/SK5322000A3/sk unknown
- 1998-10-12 WO PCT/GB1998/003067 patent/WO1999018944A1/en not_active Ceased
- 1998-10-12 OA OA1200000107A patent/OA11519A/en unknown
- 1998-10-12 YU YU28700A patent/YU28700A/sh unknown
- 1998-10-12 ID IDW20000670A patent/ID24439A/id unknown
- 1998-10-12 TR TR2000/00957T patent/TR200000957T2/xx unknown
- 1998-10-12 UA UA2000042049A patent/UA66809C2/uk unknown
- 1998-10-12 EA EA200000418A patent/EA200000418A1/ru unknown
- 1998-10-12 AU AU95471/98A patent/AU9547198A/en not_active Abandoned
- 1998-10-12 HU HU0003673A patent/HUP0003673A3/hu unknown
- 1998-10-12 CN CN98812016A patent/CN1281358A/zh active Pending
-
2000
- 2000-04-12 NO NO20001897A patent/NO20001897L/no not_active Application Discontinuation
- 2000-05-05 BG BG104405A patent/BG104405A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| YU28700A (sh) | 2003-10-31 |
| AP2000001788A0 (en) | 2000-06-30 |
| CA2305289A1 (en) | 1999-04-22 |
| OA11519A (en) | 2004-02-09 |
| EP1023057A1 (en) | 2000-08-02 |
| WO1999018944A1 (en) | 1999-04-22 |
| AU9547198A (en) | 1999-05-03 |
| PL339804A1 (en) | 2001-01-02 |
| JP2001519383A (ja) | 2001-10-23 |
| BR9815220A (pt) | 2000-11-14 |
| CN1281358A (zh) | 2001-01-24 |
| NO20001897D0 (no) | 2000-04-12 |
| CZ20001298A3 (cs) | 2001-08-15 |
| TR200000957T2 (tr) | 2000-08-21 |
| NO20001897L (no) | 2000-06-09 |
| EA200000418A1 (ru) | 2000-10-30 |
| HUP0003673A2 (hu) | 2001-10-28 |
| IL135515A0 (en) | 2001-05-20 |
| AP1223A (en) | 2003-11-13 |
| HUP0003673A3 (en) | 2001-12-28 |
| GB9721692D0 (en) | 1997-12-10 |
| BG104405A (en) | 2000-12-29 |
| UA66809C2 (uk) | 2004-06-15 |
| KR20010024482A (ko) | 2001-03-26 |
| SK5322000A3 (en) | 2000-09-12 |
| ID24439A (id) | 2000-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100671918B1 (ko) | 티아졸리딘디온, 인슐린 분비촉진제 및 디구아니드를사용한 당뇨병의 치료 | |
| UA70302C2 (uk) | Комбінація тіазолідиндіону і сульфонілсечовини, фармацевтична композиція та спосіб лікування діабету | |
| BG103966A (bg) | Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата | |
| KR20010021952A (ko) | 티아졸리딘디온, 인슐린 분비촉진제 및 알파 글루코시다제억제제를 사용한 당뇨병의 치료 | |
| KR20010013840A (ko) | 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료 | |
| HRP20000256A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| HRP20000255A2 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| US20020137773A1 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| US20010031776A1 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| MXPA00003634A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| CZ299801B6 (cs) | Farmaceutický prostredek s postupným uvolnováním a lécivo pro lécení diabetes mellitus typu 2 a stavu souvisejících s diabetes mellitus | |
| MXPA00003633A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AU4586902A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| AU4587002A (en) | Use of thiazolidinediones for the treatment of hyperglycaemia | |
| MXPA99012098A (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
| MXPA00000633A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
| MXPA99012078A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| MXPA01004826A (en) | Combinations comprising a beta-agonist and a further antidiabetic agent | |
| CZ2000174A3 (cs) | Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20041004 Year of fee payment: 7 |
|
| OBST | Application withdrawn |